Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells:: APC8015 (Provenge®)

被引：39
|
作者：
Harzstark, Andrea L. [1 ]
Small, Eric J. [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期
关键词：
dendritic cell; immunotherapy; prostate cancer; prostatic acid phosphatase; Provenge;
D O I：
10.1517/14712598.7.8.1275
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Dendritic cells are deficient both in number and function in patients with cancer. Loaded dendritic cell therapies aim to overcome this deficiency by delivering antigens to antigen-presenting cells under ex vivo conditions, improving dendritic cell function. APC8015 (Provenge((R)); Dendreon Corp., Seattle, WA) is a novel immunotherapeutic, which consists of autologous dendritic cells pulsed ex vivo with PA2024, a recombinant fusion protein consisting of granulocyte macrophage colony-stimulating factor and prostatic acid phosphatase, as an immunogenic agent. A Phase III randomized clinical trial has demonstrated a survival benefit in patients with metastatic hormone-refractory prostate cancer. This review summarizes the clinical trials using APC801 5 in prostate cancer and discusses its future role in the treatment of prostate cancer.
引用
下载
收藏
页码：1275 / 1280
页数：6
相关论文
共 50 条
  • [21] Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells
    Alexei F. Kirkin
    Karine N. Dzhandzhugazyan
    Per Guldberg
    Johnny Jon Fang
    Rikke S. Andersen
    Christina Dahl
    Jann Mortensen
    Tim Lundby
    Aase Wagner
    Ian Law
    Helle Broholm
    Line Madsen
    Christer Lundell-Ek
    Morten F. Gjerstorff
    Henrik J. Ditzel
    Martin R. Jensen
    Walter Fischer
    Nature Communications, 9
  • [22] Human cell-based artificial antigen-presenting cells for cancer immunotherapy
    Butler, Marcus O.
    Hirano, Naoto
    IMMUNOLOGICAL REVIEWS, 2014, 257 (01) : 191 - 209
  • [23] Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells
    Eggermont, Loek J.
    Paulis, Leonie E.
    Tel, Jurjen
    Figdor, Carl G.
    TRENDS IN BIOTECHNOLOGY, 2014, 32 (09) : 456 - 465
  • [24] In situ targeting of dendritic cells by antigen-loaded red blood cells: A novel approach to cancer immunotherapy
    Banz, Alice
    Cremel, Magali
    Rembert, Audrey
    Godfrin, Yann
    VACCINE, 2010, 28 (17) : 2965 - 2972
  • [25] Combination immunotherapy with rGM-CSF and rIL-4 in patients with cancer: Effects on antigen-presenting cells (APC) and APC activity.
    Roth, MD
    Gitlitz, BJ
    Kiertscher, SM
    Park, AN
    Ng, M
    Mendenhall, M
    Moldawer, N
    Figlin, RA
    FASEB JOURNAL, 1998, 12 (05): : A889 - A889
  • [26] THE INTERACTIONS BETWEEN ANTIGEN-PRESENTING CELLS (APC) AND LYMPHOCYTES-T
    COHEN, IR
    ANNALES D IMMUNOLOGIE, 1984, C135 (03): : 400 - 402
  • [27] TUMOR-IMMUNOTHERAPY WITH THE USE OF TUMOR-ANTIGEN-PULSED ANTIGEN-PRESENTING CELLS
    ZOU, JP
    SHIMIZU, J
    IKEGAME, K
    TAKIUCHI, H
    FUJIWARA, H
    HAMAOKA, T
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 35 (01) : 1 - 6
  • [28] Development of allergic rhinitis immunotherapy using antigen-loaded small extracellular vesicles
    Liu, Wen
    Ota, Maki
    Tabushi, Mayu
    Takahashi, Yuki
    Takakura, Yoshinobu
    JOURNAL OF CONTROLLED RELEASE, 2022, 345 : 433 - 442
  • [29] Antigen-loaded endoplasmic reticulum microsomes from antigen presenting cells induce potent immune responses against viral infection and cancer
    Wang, Ping
    Wang, Ping
    FASEB JOURNAL, 2008, 22
  • [30] Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer
    Schellhammer, PF
    Hershberg, RM
    WORLD JOURNAL OF UROLOGY, 2005, 23 (01) : 47 - 49
12345